Sintx Technologies Crecimiento futuro

Future controles de criterios 1/6

Se prevé que los beneficios de Sintx Technologies disminuyan a un ritmo anual de 23.7%, mientras que sus ingresos anuales crecerán a un ritmo de 19.5% por año. Se espera que el BPA crezca en un 145.4% al año.

Información clave

-27.1%

Tasa de crecimiento de los beneficios

139.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	22.1%
Tasa de crecimiento de los ingresos	12.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	31 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

LSE:0A8S - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	3	-14	N/A	-11	2
12/31/2024	3	-11	N/A	-9	1
3/31/2024	3	-9	-12	-12	N/A
12/31/2023	3	-8	-15	-14	N/A
9/30/2023	2	-14	-14	-13	N/A
6/30/2023	2	-14	-14	-13	N/A
3/31/2023	2	-14	-13	-12	N/A
12/31/2022	2	-16	-12	-10	N/A
9/30/2022	1	-10	-12	-11	N/A
6/30/2022	1	-10	-14	-11	N/A
3/31/2022	1	-10	-14	-10	N/A
12/31/2021	1	-9	-14	-10	N/A
9/30/2021	1	-9	-13	-10	N/A
6/30/2021	0	-9	-10	-10	N/A
3/31/2021	0	-11	-9	-9	N/A
12/31/2020	1	-17	-9	-9	N/A
9/30/2020	1	-16	-9	-9	N/A
6/30/2020	1	-15	-8	-8	N/A
3/31/2020	1	-14	-8	-8	N/A
12/31/2019	1	-7	-7	-6	N/A
9/30/2019	1	-8	-6	-6	N/A
6/30/2019	0	-15	-7	-7	N/A
3/31/2019	0	-22	-9	-9	N/A
12/31/2018	0	-24	-9	-9	N/A
9/30/2018	N/A	-24	-8	-8	N/A
6/30/2018	-6	-17	-7	-7	N/A
3/31/2018	-3	-9	-5	-5	N/A
12/31/2017	N/A	-6	N/A	-5	N/A
9/30/2017	4	-5	N/A	-6	N/A
6/30/2017	13	-15	N/A	-8	N/A
3/31/2017	14	-18	N/A	-8	N/A
12/31/2016	15	-21	N/A	-7	N/A
9/30/2016	17	-22	N/A	-7	N/A
6/30/2016	18	-21	N/A	-6	N/A
3/31/2016	19	-22	N/A	-8	N/A
12/31/2015	19	-24	N/A	-9	N/A
9/30/2015	20	-31	N/A	-10	N/A
6/30/2015	21	-26	N/A	-11	N/A
3/31/2015	22	-33	N/A	-15	N/A
12/31/2014	23	-33	N/A	-15	N/A
9/30/2014	23	-22	N/A	-16	N/A
6/30/2014	23	-20	N/A	-15	N/A
3/31/2014	23	-9	N/A	-11	N/A
12/31/2013	22	-8	N/A	-10	N/A
9/30/2013	23	-33	N/A	-9	N/A
6/30/2013	23	-34	N/A	-8	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 0A8S siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 0A8S siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 0A8S siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (19.5% al año) de 0A8S crezcan más rápidamente que los del mercado UK (3.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 19.5% al año) de 0A8S crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 0A8S se prevé que sea elevada dentro de 3 años.

Sintx Technologies Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

No longer forecast to breakeven

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Sintx Technologies Declares 1-for-200 Reverse Stock Split Effective May 28, 2024 to Bring it into Compliance with the Minimum Bid Price Requirements for Maintaining the Listing on the Nasdaq Capital Market

New major risk - Financial position

First quarter 2024 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2023)

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022)

Full year 2022 earnings released: US$54.67 loss per share (vs US$35.54 loss in FY 2021)

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Insufficient new directors

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021)

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million.

Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio

National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device

Insufficient new directors

Insufficient new directors

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021)

Insufficient new directors

Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million.

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020)

No longer forecast to breakeven

Insufficient new directors

SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics

SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020)

Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020)

SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications

SINTX Technologies Files Multiple New U.S. and International Patent Applications

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento